Market research
PRPH ProPhase Labs Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 313K
- P/E ratio
- Not available
- Analyst target
- 13.8
- Dividend yield
- Not available
- Beta
- 0.13
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US74345W1080
- Market cap
- 313K
- P/E ratio
- Not available
- Analyst target
- 13.8
- Dividend yield
- Not available
- Beta
- 0.13
About
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PRPH discussion.
5 years, 4 months ago
ProPhase Labs, Inc is currently in a long term downtrend where the price is trading 22.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.0.
ProPhase Labs, Inc's total revenue rose by 64.4% to $5M since the same quarter in the previous year.
Its net income has dropped by 109.4% to $-978K since the same quarter in the previous year.
Finally, its free cash flow fell by 1648.4% to $-8M since the same quarter in the previous year.
Based on the above factors, ProPhase Labs, Inc gets an overall score of 2/5.